Clusters of differentiation

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drugs in Development, 2021 Market Report - Indications, Stage of Development, Mechanism of Action, Route of Administration and Molecules - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 28, 2021
Health, General Health, Medical specialties, Branches of biology, Clusters of differentiation, Immunology, Medicine, Immune system, T cell, CD28, CD28 family receptor, Theralizumab

b'The "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nT Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021 provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nT Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drugs in Development, 2021 provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development and features dormant and discontinued projects.
  • The report analyses the pipeline products across relevant therapy areas under development targeting T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28).\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics.\n'

Arch Oncology Secures $105 Million Series C Financing

Retrieved on: 
Tuesday, April 27, 2021
Clusters of differentiation, CD47, Cancer research, Signal-regulatory protein alpha, Antibody, Branches of biology, Biology, Life sciences

Arch Oncology\xe2\x80\x99s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain, also participated in the round.

Key Points: 
  • Arch Oncology\xe2\x80\x99s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain, also participated in the round.
  • We will also explore other indications and combinations consistent with our novel mechanisms of action,\xe2\x80\x9d said Laurence Blumberg, M.D., President and Chief Executive Officer of Arch Oncology.
  • AO-176 works by blocking the \xe2\x80\x9cdon\xe2\x80\x99t eat me\xe2\x80\x9d signal enabled by CD47\xe2\x80\x99s interaction with SIRPa and inducing phagocytosis.
  • In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer.

Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate

Retrieved on: 
Monday, April 26, 2021
Branches of biology, RNA, Biology, Molecular biology, Clusters of differentiation, Small interfering RNA, TLR9, Gene silencing

City of Hope is a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases near Los Angeles, California.\nJoshua R. Lamstein, Chairman of Scopus BioPharma, stated, "The IND submission to the FDA for a Phase 1 clinical trial for our lead drug candidate is a key milestone for Scopus.

Key Points: 
  • City of Hope is a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases near Los Angeles, California.\nJoshua R. Lamstein, Chairman of Scopus BioPharma, stated, "The IND submission to the FDA for a Phase 1 clinical trial for our lead drug candidate is a key milestone for Scopus.
  • "\nScopus\' lead drug candidate encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
  • The IND submission is testament to the respective efforts and close cooperation of the Scopus and City of Hope teams.
  • The IND submission to the FDA was accomplished on time and on budget.

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

Retrieved on: 
Wednesday, April 21, 2021
Clusters of differentiation, CD47, Cancer research, Oncology

ALX Oncology\xe2\x80\x99s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.

Key Points: 
  • ALX Oncology\xe2\x80\x99s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.
  • ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
  • ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML.
  • Such forward-looking statements are based on ALX Oncology\xe2\x80\x99s beliefs and assumptions and on information currently available to it on the date of this press release.

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Immune system, Clinical medicine, Medicine, Clusters of differentiation, Cancer immunotherapy, Programmed cell death protein 1, PD-L1, Checkpoint inhibitor, Avelumab, T cell, PD-1 and PD-L1 inhibitors

Notably, the objective response rate (ORR) with the combination therapy was higher than previously reported for single agent avelumab in the PD-L1 negative / low population.

Key Points: 
  • Notably, the objective response rate (ORR) with the combination therapy was higher than previously reported for single agent avelumab in the PD-L1 negative / low population.
  • Finally, exploratory biomarker analysis from biopsies demonstrated improved penetration of killer CD8+ T cells into the tumor.\nDr.
  • This appears to enhance the efficacy of checkpoint inhibition, even in some patients who did not respond to prior anti-PD-1/L1 therapies.
  • Except as required by law, we assume no obligation to update these forward-looking statements.

Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy

Retrieved on: 
Monday, April 19, 2021
Clusters of differentiation, Immune system, Programmed cell death protein 1, Head and neck cancer, Biotechnology, Branches of biology, Health care, Life sciences, Cancer immunotherapy

To identify unrecognized regulators of cell survival, the researchers performed a whole-genome CRISPR-Cas9 screen following treatment with ionizing radiation and identified STING (stimulator of interferon genes) as an intrinsic regulator of tumor cell survival.

Key Points: 
  • To identify unrecognized regulators of cell survival, the researchers performed a whole-genome CRISPR-Cas9 screen following treatment with ionizing radiation and identified STING (stimulator of interferon genes) as an intrinsic regulator of tumor cell survival.
  • In addition, the study showed that STING overexpression restored tumor cell sensitivity to ionizing radiation and that STING loss confers resistance to DNA damaging therapies.\nAnalysis of tumors from HNSCC patient specimens showed that low STING expression is associated with poor outcomes.
  • Although many patients respond to PD-1 therapies, in some patients, the PD-1 blockade is not enough to activate immune cells.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma

Retrieved on: 
Wednesday, April 21, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Cancer treatments, Clusters of differentiation, Immune system, Antineoplastic drugs, Cancer, Melanoma, Targeted therapy, CD155, Programmed cell death protein 1, Cancer immunotherapy, PVSRIPO, Istari Oncology, PVSRIPO, ISTARI ONCOLOGY

The results of this study suggest that PVSRIPO holds promise for patients with advanced melanoma refractory to both PD-1 inhibitors and BRAF-targeted therapy.1\nTwelve patients received 1, 2, or 3 intratumoral injections of PVSRIPO at 21-day intervals.

Key Points: 
  • The results of this study suggest that PVSRIPO holds promise for patients with advanced melanoma refractory to both PD-1 inhibitors and BRAF-targeted therapy.1\nTwelve patients received 1, 2, or 3 intratumoral injections of PVSRIPO at 21-day intervals.
  • Responses were observed in both injected and noninjected tumors, suggestive of an abscopal response.
  • PVSRIPO has a distinct target (the poliovirus receptor, CD155), which is expressed on virtually all solid tumors and antigen-presenting cells.
  • A phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.

Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors

Retrieved on: 
Monday, April 19, 2021
Oncology, FDA, Health, Clinical trials, General Health, Biotechnology, Medical specialties, Clusters of differentiation, Branches of biology, Medicine, Enteroviruses, Polio, Immune system, Virotherapy, Tumor microenvironment, Poliovirus, PVSRIPO, Programmed cell death protein 1, PVSRIPO, Istari Oncology, PVSRIPO, ISTARI ONCOLOGY

LUMINOS-103 ( NCT04690699 ) is a Phase 1/2 open-label, multi-center, single-arm basket trial evaluating the administration of PVSRIPO with or without PD-1/L1 inhibitors in adult subjects with solid tumor cancers.

Key Points: 
  • LUMINOS-103 ( NCT04690699 ) is a Phase 1/2 open-label, multi-center, single-arm basket trial evaluating the administration of PVSRIPO with or without PD-1/L1 inhibitors in adult subjects with solid tumor cancers.
  • PVSRIPO enters solid tumor cells and antigen presenting cells (APCs) in the tumor microenvironment via CD155 (the poliovirus receptor).
  • "If the tumor can be biopsied, it can be injected, so there are a wide range of solid tumors we can investigate with PVSRIPO.
  • PVSRIPO has a distinct point of entry (the poliovirus receptor, CD155), which is expressed on virtually all solid tumors and antigen-presenting cells.

NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology

Retrieved on: 
Thursday, April 15, 2021
Cancer immunotherapy, Medicine, Clinical medicine, Clusters of differentiation, Health care, PD-L1, Oncology, Beth Israel Deaconess Medical Center, Immunotherapy

"\nBruno Bockorny, M.D., an oncologist from BIDMC, will serve as the Study Principal Investigator.

Key Points: 
  • "\nBruno Bockorny, M.D., an oncologist from BIDMC, will serve as the Study Principal Investigator.
  • Co-investigators from the Division of Medical Oncology and Immunotherapy Institute at BIDMC will also participate.
  • "Even for cancer typeswith significant level of PD-L1 expression, frequently, there is discordance between PD-L1 expression level and response to treatment.
  • Our study is looking at a novel way of determining responders through a blood test.

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

Retrieved on: 
Wednesday, April 14, 2021
Branches of biology, Medicine, Health sciences, Clusters of differentiation, Pharmacodynamics, Cancer immunotherapy, Immune system, TLR9, Checkpoint inhibitor, Agonist, Hydrogel

As aninnate immunestimulator, TLR9 agonist canbecombined with checkpoint inhibitors to increase itsanti-tumor effects.

Key Points: 
  • As aninnate immunestimulator, TLR9 agonist canbecombined with checkpoint inhibitors to increase itsanti-tumor effects.
  • Local injection of the TLR9 agonist is well-tolerated but the drug can degrade in the local tissues or dissipate from the site of action rapidly, resulting in reducedefficacy.
  • GeneLeap\'s researchers have conducted preclinical studies in a mouse tumor model to examine whether a single dose of Hydrogel encapsulated TLR9 agonist can be effective over a longer period in immune activation without toxicity.\nThe current preclinical study showed that a single administration of hydrogel encapsulated TLR9 agonist demonstrates tumor growth inhibition and non-toxicity similar to that of a multiple dose of TLR9 agonist without hydrogel encapsulation.
  • This indicates that for those patients who are resistant or refractory to checkpoint inhibitors, hydrogel encapsulated TLR9 agonist could enhance the immune response to checkpoint inhibitors for a longer time.